The Q1 print is largely in-line with expectations for a clinical-stage biotech. Key catalysts to watch: EHA poster presentation (June 12), ASCO trial-in-progress poster (May 29-June 2), and initial ORR data from Phase 2 MOMENTUM in 2H 2027. The Roche collaboration provides non-dilutive capital and validates the DAC platform. The CFT8919 discontinuation outside China removes a pipeline asset but likely already discounted. Monitor cash burn rate and any future partnership milestones.
Price Chart
Executive Summary
C4 Therapeutics reported Q1 2026 revenue of $6.2M (down 14% YoY from $7.2M) and a net loss per share of -$0.20 (improved from -$0.37 YoY). The company highlighted clinical progress with cemsidomide (Phase 2 MOMENTUM enrolling, Phase 1b combo with elranatamab dosed) and a new Roche collaboration for degrader-antibody conjugates, but also announced it will not advance CFT8919 outside Greater China. Cash burn continues with $268.3M at quarter-end, providing runway to end of 2028.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $6.2M vs $7.2M YoY (-14%), driven by conclusion of Merck collaboration and prioritization of one KRAS project
- Net loss per share -$0.20 vs -$0.37 YoY, improved on lower R&D spend ($24.6M vs $27.1M)
- Cash, cash equivalents and marketable securities $268.3M as of March 31, 2026, down from $297.1M at Dec 31, 2025
- Cash runway expected to fund operations to end of 2028
- Phase 2 MOMENTUM trial of cemsidomide + dexamethasone in 4L+ multiple myeloma enrolling, enrollment completion expected Q1 2027
- Phase 1b trial of cemsidomide + elranatamab initiated, first patient dosed March 2026
- Additional Phase 1b combo trial with approved MM therapies expected to initiate in first half of 2027
- C4T entered new collaboration with Roche in April 2026 for degrader-antibody conjugates, received $20M upfront payment in May 2026
- Company decided not to advance CFT8919 (EGFR L858R degrader) outside Greater China
- Received $2M milestone payment from Biogen for second degrader delivered to clinical development
Financial Impact
Revenue decline of ~14% YoY to $6.2M; net loss improved to -$25.1M from -$26.3M; cash burn ~$28.8M in Q1
Risk Factors
- Revenue concentration on collaboration agreements with no approved products
- Clinical trial execution risk for cemsidomide (Phase 2 MOMENTUM, Phase 1b combo)
- Cash burn of ~$28.8M/quarter may require future capital raises before reaching profitability
- CFT8919 discontinuation outside China narrows pipeline optionality
- Dependence on partnership milestones for non-dilutive funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-033861 |
| Document: maycorporatedeck_finalx5.htm | 0001628280-26-033861 |
| Document: cccc-20260512.htm | 0001628280-26-033861 |
| Document: 0001628280-26-033861-index-headers.html | 0001628280-26-033861 |
| Document: 0001628280-26-033861-index.html | 0001628280-26-033861 |
| Document: 0001628280-26-033861.txt | 0001628280-26-033861 |
| 8-K Data (Synthetic) | 0001628280-26-033861 |
Track record
19 reports on CCCC
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers